Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2

D. Gareth Evans, Michel Kalamarides, Kim Hunter-Schaedle, Jaishri Blakeley, Jeffrey Allen, Dusica Babovic-Vuskanovic, Allan Belzberg, Gideon Bollag, Ruihong Chen, Emmanuelle DiTomaso, John Golfinos, Gordon Harris, Abraham Jacob, Ganjam V. Kalpana, Matthias Karajannis, Bruce Korf, Razelle Kurzrock, Meng Law, Andrea McClatchey, Roger PackerPamela Roehm, Allan Rubenstein, William Slattery, James H. Tonsgard, D. Bradley Welling, Brigitte Widemann, Kaleb Yohay, Marco Giovannini

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. Experimental Design: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. Results: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. Conclusions: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.

Original languageEnglish (US)
Pages (from-to)5032-5039
Number of pages8
JournalClinical Cancer Research
Volume15
Issue number16
DOIs
StatePublished - Aug 15 2009

Fingerprint

Neurofibromatosis 2
Clinical Trials
Vestibulocochlear Nerve
Education
Ependymoma
Central Nervous System Neoplasms
Neurilemmoma
Meningioma
Biotechnology
Industry
Research Design
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evans, D. G., Kalamarides, M., Hunter-Schaedle, K., Blakeley, J., Allen, J., Babovic-Vuskanovic, D., ... Giovannini, M. (2009). Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clinical Cancer Research, 15(16), 5032-5039. https://doi.org/10.1158/1078-0432.CCR-08-3011

Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. / Evans, D. Gareth; Kalamarides, Michel; Hunter-Schaedle, Kim; Blakeley, Jaishri; Allen, Jeffrey; Babovic-Vuskanovic, Dusica; Belzberg, Allan; Bollag, Gideon; Chen, Ruihong; DiTomaso, Emmanuelle; Golfinos, John; Harris, Gordon; Jacob, Abraham; Kalpana, Ganjam V.; Karajannis, Matthias; Korf, Bruce; Kurzrock, Razelle; Law, Meng; McClatchey, Andrea; Packer, Roger; Roehm, Pamela; Rubenstein, Allan; Slattery, William; Tonsgard, James H.; Welling, D. Bradley; Widemann, Brigitte; Yohay, Kaleb; Giovannini, Marco.

In: Clinical Cancer Research, Vol. 15, No. 16, 15.08.2009, p. 5032-5039.

Research output: Contribution to journalArticle

Evans, DG, Kalamarides, M, Hunter-Schaedle, K, Blakeley, J, Allen, J, Babovic-Vuskanovic, D, Belzberg, A, Bollag, G, Chen, R, DiTomaso, E, Golfinos, J, Harris, G, Jacob, A, Kalpana, GV, Karajannis, M, Korf, B, Kurzrock, R, Law, M, McClatchey, A, Packer, R, Roehm, P, Rubenstein, A, Slattery, W, Tonsgard, JH, Welling, DB, Widemann, B, Yohay, K & Giovannini, M 2009, 'Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2', Clinical Cancer Research, vol. 15, no. 16, pp. 5032-5039. https://doi.org/10.1158/1078-0432.CCR-08-3011
Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clinical Cancer Research. 2009 Aug 15;15(16):5032-5039. https://doi.org/10.1158/1078-0432.CCR-08-3011
Evans, D. Gareth ; Kalamarides, Michel ; Hunter-Schaedle, Kim ; Blakeley, Jaishri ; Allen, Jeffrey ; Babovic-Vuskanovic, Dusica ; Belzberg, Allan ; Bollag, Gideon ; Chen, Ruihong ; DiTomaso, Emmanuelle ; Golfinos, John ; Harris, Gordon ; Jacob, Abraham ; Kalpana, Ganjam V. ; Karajannis, Matthias ; Korf, Bruce ; Kurzrock, Razelle ; Law, Meng ; McClatchey, Andrea ; Packer, Roger ; Roehm, Pamela ; Rubenstein, Allan ; Slattery, William ; Tonsgard, James H. ; Welling, D. Bradley ; Widemann, Brigitte ; Yohay, Kaleb ; Giovannini, Marco. / Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 16. pp. 5032-5039.
@article{0dd34b2788144aa2acea212768a16619,
title = "Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2",
abstract = "Purpose: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. Experimental Design: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. Results: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. Conclusions: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.",
author = "Evans, {D. Gareth} and Michel Kalamarides and Kim Hunter-Schaedle and Jaishri Blakeley and Jeffrey Allen and Dusica Babovic-Vuskanovic and Allan Belzberg and Gideon Bollag and Ruihong Chen and Emmanuelle DiTomaso and John Golfinos and Gordon Harris and Abraham Jacob and Kalpana, {Ganjam V.} and Matthias Karajannis and Bruce Korf and Razelle Kurzrock and Meng Law and Andrea McClatchey and Roger Packer and Pamela Roehm and Allan Rubenstein and William Slattery and Tonsgard, {James H.} and Welling, {D. Bradley} and Brigitte Widemann and Kaleb Yohay and Marco Giovannini",
year = "2009",
month = "8",
day = "15",
doi = "10.1158/1078-0432.CCR-08-3011",
language = "English (US)",
volume = "15",
pages = "5032--5039",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2

AU - Evans, D. Gareth

AU - Kalamarides, Michel

AU - Hunter-Schaedle, Kim

AU - Blakeley, Jaishri

AU - Allen, Jeffrey

AU - Babovic-Vuskanovic, Dusica

AU - Belzberg, Allan

AU - Bollag, Gideon

AU - Chen, Ruihong

AU - DiTomaso, Emmanuelle

AU - Golfinos, John

AU - Harris, Gordon

AU - Jacob, Abraham

AU - Kalpana, Ganjam V.

AU - Karajannis, Matthias

AU - Korf, Bruce

AU - Kurzrock, Razelle

AU - Law, Meng

AU - McClatchey, Andrea

AU - Packer, Roger

AU - Roehm, Pamela

AU - Rubenstein, Allan

AU - Slattery, William

AU - Tonsgard, James H.

AU - Welling, D. Bradley

AU - Widemann, Brigitte

AU - Yohay, Kaleb

AU - Giovannini, Marco

PY - 2009/8/15

Y1 - 2009/8/15

N2 - Purpose: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. Experimental Design: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. Results: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. Conclusions: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.

AB - Purpose: Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder associated primarily with bilateral schwannomas seen on the superior vestibular branches of the eighth cranial nerves. Significant morbidity can result from surgical treatment of these tumors. Meningiomas, ependymomas, and other benign central nervous system tumors are also common in NF2. The lack of effective treatments for NF2 marks an unmet medical need. Experimental Design: Here, we provide recommendations from a workshop, cochaired by Drs. D. Gareth Evans and Marco Giovannini, of 36 international researchers, physicians, representatives of the biotechnology industry, and patient advocates on how to accelerate progress toward NF2 clinical trials. Results: Workshop participants reached a consensus that, based on current knowledge, the time is right to plan and implement NF2 clinical trials. Obstacles impeding NF2 clinical trials and how to address them were discussed, as well as the candidate therapeutic pipeline for NF2. Conclusions: Both phase 0 and phase II NF2 trials are near-term options for NF2 clinical trials. The number of NF2 patients in the population remains limited, and successful recruitment will require ongoing collaboration efforts between NF2 clinics.

UR - http://www.scopus.com/inward/record.url?scp=68149180536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68149180536&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-3011

DO - 10.1158/1078-0432.CCR-08-3011

M3 - Article

C2 - 19671848

AN - SCOPUS:68149180536

VL - 15

SP - 5032

EP - 5039

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 16

ER -